A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Muscle Invasive Bladder Neoplasms

Interventions

DRUG: TAR-210
DRUG: Mitomycin C
DRUG: Gemcitabine

Sponsor

Janssen Research & Development, LLC